Pharma Business review is using cookies

ContinueLearn More
Close

News

October 15, 2018

Mereo completes patient enrollment for brittle bone disease trial

Mereo BioPharma Group, a UK-based specialty biopharma company, has completed patient enrollment for a phase 2b clinical trial of BPS-804 (Setrusumab) for the treatment of osteogenesis imperfecta (OI).

Mereo completes patient enrollment for brittle bone disease trial